| Median (IQR) |
Rosiglitazone
(n=29) |
P
(within group) |
Placebo
(n=32) |
P
(within group) |
P
(between groups) |
| Limb fat, grams |
+448 (138, 1670) |
<0.001 |
+153 (-100, 682) |
<0.03 |
0.02 |
| BMI, kg/m2 |
+ 0.9 (0.08, 1.6) |
<0.001 |
+ 0.5 (-0.08, 1.3) |
0.03 |
0.24 |
| F2 isoprostanes, ng/mL |
+0.019 (-0.002, 0.036) |
0.003 |
+0.017 (-0.003, 0.032) |
0.001 |
0.078 |
| sTNFR-I, pg/mL |
+733.8 (318.5, 9891.3) |
<0.001 |
+973.3 (373.3, 8662.9) |
<0.001 |
0.98 |
| sTNFR-II, pg/mL |
+1722.4 (872.9, 5951.9) |
<0.001 |
+1586.9 (994.7, 5552.8) |
<0.001 |
0.97 |
| IL-6 , pg/mL |
+0.2 (-9.0, 34.2) |
0.30 |
+1.4 (-5.2, 16.9) |
0.29 |
0.92 |
| hs CRP, mg/L |
-4.6 (-11.1, -0.9) |
<0.001 |
-1.5 (-8.8, 0.18) |
0.02 |
0.11 |
| mtDNA, copies/cell (n=57) |
+41 (-14, 66)
(n=27) |
0.08 |
+29 (-36, 67)
(n=30) |
0.38 |
0.54 |
| PPAR-γ/ GAPDH ratio
(n=57) |
-6.8% (-7.2%, -0.4%)
(n=27) |
0.32 |
-0.5% (-7.4%, 4.3%)
(n=30) |
0.86 |
0.54 |
|
